DaVita reported Q2 earnings on August 4 and the market's reaction has been swift — the stock dropped 2.4% on the day and is now down nearly 5% on the week to $227.99, reversing most of the pre-earnings momentum that carried shares to $240 just days ago.
The post-earnings move has pushed the stock below most analyst price targets for the first time in weeks. The mean target now sits at $220.71, meaning the Street is actually pricing in a slight pullback from current levels — an unusual inversion after months of analysts chasing the stock higher. The most recent action came from Barclays, which raised its target to $224 from $218 this morning while holding its Equal-Weight rating — a modest acknowledgment of improved fundamentals without any change in conviction. Earlier in July, UBS held a $270 target with a Buy, and Truist sat at $250 with a Hold. Both those targets remain above the current price, but the consensus picture is mixed: bulls point to DaVita's dominant 35% share of U.S. dialysis clinics, roughly 280,000 patients annually, and a near-decade-long relationship with Berkshire Hathaway as anchor investor. Bears flag the structural vulnerability of a business where two-thirds of U.S. revenue flows through Medicare reimbursement rates, with profit disproportionately reliant on the 10% of patients covered by commercial insurers. EPS forward estimates rank in the 82nd percentile for year-on-year growth, and the stock has beaten consensus expectations at a rate that places it in the 77th percentile on EPS surprise — but the re-rating that drove the stock from the $150s to $240 may already be in the price.
Positioning in the lending market is relaxed, which keeps squeeze pressure off the downside. Short interest has barely moved on the week — down just 0.06% — and remains at 6.3% of the free float, roughly 4.47 million shares. That is actually a tick higher than reported Monday, confirming the week's early note that bears were retreating has given way to mild re-engagement after the print. Borrow availability remains very loose at around 490%, meaning there are nearly five shares available for every one already borrowed — far from the tightest level of the past year (165%). Cost to borrow has climbed 33% over the week to 0.52%, a noticeable move in percentage terms but still negligible in absolute cost. Options positioning is slightly more cautious than usual: the put/call ratio at 0.617 is modestly above its 20-day average of 0.600, about one standard deviation elevated, but nowhere near the 52-week high of 1.86. The overall lending setup reads as comfortable rather than pressured — there is room for short interest to build if sentiment continues to deteriorate, without any mechanical squeeze friction.
The insider picture is worth noting. CEO Javier Rodriguez sold roughly 70,000 shares in mid-June for approximately $14.5 million combined, and Berkshire Hathaway trimmed its position by about 183,000 shares at the end of July — a $36.5 million reduction executed near the recent highs around $199.55. Berkshire still controls nearly 45% of the company, so this is a marginal adjustment rather than a directional statement, but the timing — just before the Q2 release — adds context to the post-earnings weakness. Net insider activity over the past 90 days shows roughly 361,000 shares sold in aggregate for about $72 million in proceeds. There are no purchases on record in the window.
The next earnings event is scheduled for October 30, giving roughly three months for the Street to reassess whether the post-earnings selloff represents a reset or the start of a longer re-rating. The key variable to watch is whether analyst targets begin to converge downward toward the $220 consensus — or whether UBS and Truist hold their more constructive postures as Q3 operating data filters through.
See the live data behind this article on ORTEX.
Open DVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
